AstraZeneca Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
317 result(s) found, displaying 21 to 30
-
Australian Public Assessment Report (AusPAR)Enhertu (trastuzumab deruxtecan) was approved to treat adult patients with unresectable or metastatic HER2-low breast cancer.
-
Sep-2024Prescription medicine evaluationActive ingredient: trastuzumab deruxtecan.
-
Sep-2024Prescription medicine evaluationActive ingredient: sipavibart.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LOKELMA sodium zirconium cyclosilicate hydrate 5 g powder for oral suspension sachet.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LOKELMA sodium zirconium cyclosilicate hydrate 10 g powder for oral suspension sachet.
-
Australian Public Assessment Report (AusPAR)Sidapvia (dapagliflozin+sitagliptin), a new drug combination, has been approved to treat type 2 diabetes mellitus in adults, as an adjunct to diet and exercise to improve glycaemic control.
-
-
Australian Public Assessment Report (AusPAR)Lynparza (olaparib) has been approved for the treatment of BRCA-mutated HER2-negative high risk early breast cancer and metastatic castration-resistant prostate cancer.
-
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd